4IB4 : Crystal structure of the chimeric protein of 5-HT2B-BRIL in complex with ergotamine

  • Vadim Cherezov (Contributor)
  • Vsevolod Katritch (Contributor)
  • Raymond C. Stevens (Contributor)
  • Gye Won Han (Contributor)
  • Xi Ping Huang (Contributor)
  • Bryan L. Roth (Contributor)
  • Daniel Wacker (Contributor)
  • Wei Liu (Contributor)
  • Xi Ping Huang (Contributor)
  • Yi Jiang (Contributor)
  • H. Eric Xu (Contributor)
  • Chong Wang (Contributor)
  • John D. McCorvy (Contributor)
  • Gye Won Han (Contributor)



Experimental Technique/Method:X-RAY DIFFRACTION
Release Date:2013-03-13
Deposition Date:2012-12-07
Revision Date:2013-04-03#2013-04-10#2013-05-15#2017-06-07#2017-11-15
Molecular Weight:51711.34
Macromolecule Type:Protein
Residue Count:430
Atom Site Count:3055

Drugs active at G protein-coupled receptors (GPCRs) can differentially modulate either canonical or noncanonical signaling pathways via a phenomenon known as functional selectivity or biased signaling. We report biochemical studies showing that the hallucinogen lysergic acid diethylamide, its precursor ergotamine (ERG), and related ergolines display strong functional selectivity for β-arrestin signaling at the 5-HT2B 5-hydroxytryptamine (5-HT) receptor, whereas they are relatively unbiased at the 5-HT1B receptor. To investigate the structural basis for biased signaling, we determined the crystal structure of the human 5-HT2B receptor bound to ERG and compared it with the 5-HT1B/ERG structure. Given the relatively poor understanding of GPCR structure and function to date, insight into different GPCR signaling pathways is important to better understand both adverse and favorable therapeutic activities.
Date made available2013

Cite this